Hepatotoxicity related to citalopram intake: A case report

International Journal of Risk and Safety in Medicine

Volumn 22, Issue 1, 2010, Pages 1-5

  Hunfeld, Nicole G M ^a,b   Ten Berge, Rosita L ^a   LeBrun, Paul P H ^a,b   Smith, Sierd J ^a   Melief, Piet H G J ^a  

^a HAGA HOSPITAL   (Netherlands)

^b Central Hospital Pharmacy   (Netherlands)

Author keywords

Case report; Citalopram; Hepatotoxicity

Indexed keywords

ALENDRONIC ACID; BLOOD CLOTTING FACTOR 5; CALCIUM CARBONATE; CARBAMAZEPINE; CARBASALATE CALCIUM; CITALOPRAM; ETIRACETAM; LIVER ENZYME;

AGED; ANAMNESIS; ARTICLE; BLOOD ANALYSIS; CASE REPORT; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER TOXICITY;

EID: 77949555394     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: 10.3233/JRS-2010-0486     Document Type: Article

References (8)

1. C. de La Serna Higuera, A. Perez Villoria, S. Rodriguez Gomez, J. Martinez Moreno, A. Betancourt Gonzalez and M. Martin Arribas, Alendronate-induced hepatocellular lesion, Gastroenterol Hepatol 24(5) (2001), 244-246.
2. J. de Wilde, C. Mertens, K.F. Overo and H.E. Petersen, Citalopram versus mianserin, A controlled, double-blind trial in depressed patients, Acta Psychiatr Scand 72(1) (1985), 89-96.
3. A. Halabe, B.M. Lifschitz and J. Azuri, Liver damage due to alendronate, N Engl J Med 343(5) (2000), 365-366.
4. R.J. Milne and K.L. Goa, Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness, Drugs 41(3) (1991), 450-477.
5. V.J. Navarro and J.R. Senior, Drug-related hepatotoxicity, N Engl J Med 354(7) (2006), 731-739.
6. Netherlands Pharmacovigilance Centre, http://www.lareb.nl, accessed August 10, 2008.
7. SPC of alendronate, http://www.cbg-meb.nl, accessed August 10, 2008.
8. SPC of citalopram, http://www.cbg-meb.nl, accessed August 10, 2008.